Evidence that the plant cannabinoid cannabigerol is a highly potent α2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist

被引:158
作者
Cascio, M. G. [1 ]
Gauson, L. A. [1 ]
Stevenson, L. A. [1 ]
Ross, R. A. [1 ]
Pertwee, R. G. [1 ]
机构
[1] Univ Aberdeen, Sch Med Sci, Inst Med Sci, Aberdeen AB25 2ZD, Scotland
基金
美国国家卫生研究院;
关键词
cannabigerol; CP55940; mouse vas deferens; alpha(2)-adrenoceptor; 5-HT1A receptor; CB1; receptor; clonidine; dexmedetomidine; maprotiline; R-(+)-8-hydroxy-2-(di-n-propylamino)tetralin; MOUSE VAS-DEFERENS; PHARMACOLOGICAL PROFILE; CB1; NORADRENALINE; HASHISH; RELEASE; DELTA(9)-TETRAHYDROCANNABIVARIN; ADRENOCEPTORS; CONSTITUENTS; CANNABIDIOL;
D O I
10.1111/j.1476-5381.2009.00515.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and purpose: Cannabis is the source of at least seventy phytocannabinoids. The pharmacology of most of these has been little investigated, three notable exceptions being Delta(9)-tetrahydrocannabinol, cannabidiol and Delta(9)-tetrahydrocannabivarin. This investigation addressed the question of whether the little-studied phytocannabinoid, cannabigerol, can activate or block any G protein-coupled receptor. Experimental approach: The [S-35]GTP gamma S binding assay, performed with mouse brain membranes, was used to test the ability of cannabigerol to produce G protein-coupled receptor activation or blockade. Its ability to displace [H-3]CP55940 from mouse CB1 and human CB2 cannabinoid receptors and to inhibit electrically evoked contractions of the mouse isolated vas deferens was also investigated. Key results: In the brain membrane experiments, cannabigerol behaved as a potent alpha(2)-adrenoceptor agonist (EC50 = 0.2 nM) and antagonized the 5-HT1A receptor agonist, R-(+)-8-hydroxy-2-(di-n-propylamino)tetralin (apparent K-B = 51.9 nM). At 10 mu M, it also behaved as a CB1 receptor competitive antagonist. Additionally, cannabigerol inhibited evoked contractions of the vas deferens in a manner that appeared to be alpha(2)-adrenoceptor-mediated (EC50 = 72.8 nM) and displayed significant affinity for mouse CB1 and human CB2 receptors. Conclusions and implications: This investigation has provided the first evidence that cannabigerol can activate alpha(2)-adrenoceptors, bind to cannabinoid CB1 and CB2 receptors and block CB1 and 5-HT1A receptors. It will now be important to investigate why cannabigerol produced signs of agonism more potently in the [S-35]GTP gamma S binding assay than in the vas deferens and also whether it can inhibit noradrenaline uptake in this isolated tissue and in the brain. British Journal of Pharmacology (2010) 159, 129-141; doi:10.1111/j.1476-5381.2009.00515.x; published online 4 December 2009
引用
收藏
页码:129 / 141
页数:13
相关论文
共 38 条
[1]   Guide to receptors and channels (GRAC), 3rd edition [J].
Alexander, Stephen P. H. ;
Mathie, Alistair ;
Peters, John A. .
BRITISH JOURNAL OF PHARMACOLOGY, 2008, 153 :S1-S209
[2]  
BARBACCIA ML, 1986, J PHARMACOL EXP THER, V236, P307
[3]   Evidence for a new G protein-coupled cannabinoid receptor in mouse brain [J].
Breivogel, CS ;
Griffin, G ;
Di Marzo, V ;
Martin, BR .
MOLECULAR PHARMACOLOGY, 2001, 60 (01) :155-163
[4]  
CASCIO MG, 2009, S CANN BURL VERM INT, P73
[5]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[6]   Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8 [J].
De Petrocellis, Luciano ;
Vellani, Vittorio ;
Schiano-Moriello, Aniello ;
Marini, Pietro ;
Magherini, Pier Cosimo ;
Orlando, Pierangelo ;
Di Marzo, Vincenzo .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 325 (03) :1007-1015
[7]   ISOLATION AND STRUCTURE OF A BRAIN CONSTITUENT THAT BINDS TO THE CANNABINOID RECEPTOR [J].
DEVANE, WA ;
HANUS, L ;
BREUER, A ;
PERTWEE, RG ;
STEVENSON, LA ;
GRIFFIN, G ;
GIBSON, D ;
MANDELBAUM, A ;
ETINGER, A ;
MECHOULAM, R .
SCIENCE, 1992, 258 (5090) :1946-1949
[8]   Chemical constituents of marijuana: The complex mixture of natural cannabinoids [J].
ElSohly, MA ;
Slade, D .
LIFE SCIENCES, 2005, 78 (05) :539-548
[9]   A PHARMACOLOGICAL PROFILE OF THE SELECTIVE SILENT 5-HT1A RECEPTOR ANTAGONIST, WAY-100635 [J].
FORSTER, EA ;
CLIFFE, IA ;
BILL, DJ ;
DOVER, GM ;
JONES, D ;
REILLY, Y ;
FLETCHER, A .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 281 (01) :81-88
[10]  
GAONI Y, 1964, P CHEM SOC LONDON, P82